Catalyst Wire Dossier Catalyst Wire Dossier

Elexacaftor (VX-661)

elexacaftor · Vertex Pharmaceuticals Incorporated
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Elexacaftor (VX-661), covering 2018-06-12 to 2018-06-12. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation [Phase 3]

See pricing